Cerium Oxide/Graphene Oxide Hybrid: Synthesis, Characterization, and Evaluation of Anticancer Activity in a Breast Cancer Cell Line (MCF-7)
Open Access
- 12 February 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 531
Abstract
In the present study, we used a simple ultrasonic approach to develop a Cerium oxide/Graphene oxide hybrid (CeO2/GO hybrid) nanocomposite system. Particle size analysis, Fourier Transform Infrared Spectroscopy (FTIR), Scanning Electron Microscopy (SEM), and X-ray Diffraction (XRD) have been used to analyze the physio-chemical characteristics of the developed nanocomposite. The synthesized hybrid system has also been examined to assess its anticancer capability against MCF-7 cell lines and normal cell lines at different sample concentrations, pH values, and incubation intervals using an antiproliferative assay test. The test results demonstrate that as sample concentration rises, the apoptotic behavior of the CeO2/GO hybrid in the MCF-7 cell line also rises. The IC50 was 62.5 µg/mL after 72 h of incubation. Cytotoxicity of cisplatin bound CeO2/GO hybrid was also tested in MCF-7 cell lines. To identify apoptosis-associated alterations of cell membranes during the process of apoptosis, a dual acridine orange/ethidium bromide (AO/EB) fluorescence staining was carried out at three specified doses (i.e., 1000 µg/mL, 250 µg/mL, and 62.5 µg/mL of CeO2/GO hybrid). The color variations from both live (green) and dead (red) cells were examined using fluorescence microscopy under in vitro conditions. The quantitative analysis was performed using flow cytometry to identify the cell cycle at which the maximum number of MCF-7 cells had been destroyed as a result of interaction with the developed CeO2/GO hybrid (FACS study). According to the results of the FACS investigation, the majority of cancer cells were inhibited at the R3 (G2/M) phase. Therefore, the CeO2/GO hybrid has successfully showed enhanced anticancer efficacy against the MCF-7 cell line at the IC50 concentration. According to the current study, the CeO2/GO platform can be used as a therapeutic platform for breast cancer. The synergetic effects of the developed CeO2/GO hybrid with the MCF-7 cell line are presented.Keywords
Funding Information
- King Saud University (RSPD2023R665)
This publication has 40 references indexed in Scilit:
- Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical ApplicationsChemical Reviews, 2012
- Optical nano-imaging of gate-tunable graphene plasmonsNature, 2012
- Magnetite nanoparticles as smart carriers to manipulate the cytotoxicity of anticancer drugs: magnetic control and pH-responsive releaseJournal of Materials Chemistry, 2012
- In vivo targeting and positron emission tomography imaging of tumor vasculature with 66Ga-labeled nano-grapheneBiomaterials, 2012
- In Vivo Targeting and Imaging of Tumor Vasculature with Radiolabeled, Antibody-Conjugated NanographeneACS Nano, 2012
- A cerium oxide nanoparticle-based device for the detection of chronic inflammation via optical and magnetic resonance imagingNanoscale, 2012
- pH-Tunable Oxidase-Like Activity of Cerium Oxide Nanoparticles Achieving Sensitive Fluorigenic Detection of Cancer Biomarkers at Neutral pHAnalytical Chemistry, 2011
- The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric NanoparticlesMolecular Pharmaceutics, 2010
- Establishment of in-vitro models of chemotherapy resistanceAnti-Cancer Drugs, 2007
- Anticancer Efficacies of Cisplatin-Releasing pH-Responsive NanoparticlesBiomacromolecules, 2006